Phase 3 Trials of C3G Therapies

C3 glomerulopathy (C3G) is a rare, progressive kidney disease in which overactivation of the alternative complement pathway causes deposits of C3 protein to build up in the glomeruli. This triggers inflammation and glomerular damage that results in proteinuria, hematuria, and reduced kidney function.

At ASN Kidney Week 2024, Carla Nester, MD, presented findings of two phase 3 trials of C3G therapies. In a high-impact trials session (SA-OR92), she shared findings from the VALIANT study of Apellis’ pegcetacoplan. In another oral session (SA-OR66), she shared 12-month results from APPEAR-C3G, which focused on Novartis’ iptacopan. Dr. Nester spoke with Nephrology Times about both studies.